Trial Profile
A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ORION
- Sponsors AstraZeneca
- 12 Jan 2024 Planned End Date changed from 29 Sep 2024 to 27 Sep 2024.
- 28 Jun 2023 Results published in the Journal of Thoracic Oncology
- 17 Mar 2023 Planned End Date changed from 29 Dec 2023 to 29 Sep 2024.